製薬・バイオテクノロジー業界における創薬段階の提携条件および契約 (2020～2025年)

当レポートでは、製薬・バイオテクノロジー業界における創薬段階の提携条件および契約について調査し、企業が創薬段階の提携契約を締結する方法と理由、およびこれらの契約を支える財務的・戦略的条件について、データに基づいて包括的に分析しています。また、本レポートは、製薬・バイオテクノロジー業界における初期段階の提携を定義する構造、交渉力学、財務上の考慮事項に関する深い洞察を提供します。

創薬段階において、ライセンシング契約は通常、ライセンシーにライセンサーの製品または技術をさらに開発する権利またはオプションを付与するものです。これらの契約は多くの場合、共同研究開発 (R&D) から始まり、商業化契約につながる可能性のある複数の要素を含んでいます。

本レポートは、ヘルスケア分野における最新の創薬段階の契約の詳細な内訳を提供し、企業が市場動向を把握し、競合の契約構造を評価し、自社の交渉戦略を最適化するのに役立ちます。

本レポートは以下の内容を提供します：

• 2020年以降のバイオ医薬品業界における創薬段階の取引動向の分析
• 契約一時金、マイルストーン、ロイヤルティなどの財務構造に関する洞察
• 実際の創薬段階の契約に関するケーススタディ
• 2,690件以上の創薬段階案件へのアクセス (入手可能な場合は契約記録付き)
• 2020年以降もっとも活発な創薬段階のディールメーカーのプロファイル
• 最高額の創薬段階案件の詳細分析

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 企業が臨床段階で提携する理由

• 創薬段階の提携の役割
  • 創薬段階でのインライセンス
  • 創薬段階でのライセンス供与
• 創薬段階、前臨床段階、臨床段階の取引の違い
• 創薬段階の提携契約を締結する理由
  • ライセンサーが創薬段階の取引に参加する理由
  • ライセンシーが創薬段階の取引に参加する理由
• 創薬段階の提携取引の将来

第3章 創薬段階の取引戦略と構造

• 企業はどの段階で提携するか?
  • 製薬/バイオテクノロジー分野での早期提携
  • 製薬/バイオテクノロジー分野での提携
• 初期段階と後期段階の提携：リスクとコストの比較
• 企業は創薬、前臨床、臨床段階の提携にいくら費やしているか?
• 純粋な提携契約と複数コンポーネント提携契約
• 純粋なライセンシング契約構造
  • 純粋なライセンシング契約の例
  • ケーススタディ
• 複数コンポーネント創薬段階の提携契約
  • 複数コンポーネントから成る初期段階条項の例
  • ケーススタディ

第4章 創薬段階の提携における支払い戦略

• 創薬段階の支払い戦略
• 支払いオプション
  • ヘッドライン
  • アップフロント
  • ローン
  • 転換ローン
  • 公平性
  • 研究開発資金
  • ライセンシング料
  • マイルストーン
  • ロイヤリティ
  • クイッズ
  • オプション

第5章 創薬段階の取引の動向

• 長期創薬段階の提携
• 創薬段階の提携：取引タイプ別
• 創薬段階の提携：疾患タイプ別
• 創薬段階の提携：技術タイプ別
• もっとも活発な企業による創薬段階の提携

第6章 創薬段階の提携の支払い条件

• 創薬段階の支払い条件に関するガイドライン
  • アップフロント
  • マイルストーン
  • ロイヤリティ
• 創薬段階の支払い条件：取引データ分析
  • 公開データ
  • 調査データ
• 支払条件分析
  • 創薬段階のヘッドライン額
  • 創薬段階の取引のアップフロント支払い
  • 創薬段階の取引のマイルストーン支払い
  • 創薬段階のロイヤルティ率

第7章 主な創薬段階の取引

• 上位の創薬段階の取引：金額別

第8章 創薬段階のディールメーカー上位25社

• もっとも活発な創薬段階のディールメーカー上位25社

第9章 創薬段階の提携契約ディレクトリ

• 2020年から2025年までの創薬段階の取引契約

第10章 創薬段階の取引：開発段階別

• 創薬段階別の取引

付録

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025)

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report offers a comprehensive, data-driven analysis of how and why companies engage in discovery-stage partnering deals and the financial and strategic terms underpinning these agreements. This essential industry resource provides deep insights into the structure, negotiation dynamics, and financial considerations that define early-stage partnerships in the pharmaceutical and biotech sectors.

At the discovery stage, licensing agreements typically grant the licensee rights or options to further develop a licensor's product or technology. These agreements are often multi-component, beginning with collaborative research and development (R&D) and potentially leading to commercialization agreements.

This report provides a detailed breakdown of the latest discovery-stage agreements in the healthcare sector, helping companies identify market trends, evaluate competitive deal structures, and optimize their own negotiation strategies.

A Must-Have Resource for Biotech and Pharma Dealmakers

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report is an indispensable resource for business development, legal, and financial professionals involved in biopharma dealmaking.

With comprehensive insights, a vast deal database, and direct access to contract documents, this report serves as the ultimate tool for:

• Benchmarking deal structures and financial terms
• Optimizing negotiation strategies
• Assessing potential partners' flexibility and deal-making behavior
• Identifying trends and best practices in discovery-stage partnerships
• For those looking to navigate the complex landscape of discovery-stage partnering, this report offers the clarity, data, and strategic guidance needed to secure high-value agreements with the right partners.
• Why This Report is Essential for Dealmakers
• Gaining insight into the flexibility and negotiation strategies of potential partners is crucial in structuring a successful discovery-stage deal. While headline financial terms (e.g., upfront payments, milestones, and royalties) provide a broad overview, contract documents offer a deeper understanding of the actual triggers and conditions for these payments-critical details that press releases and traditional databases often omit.
• This report contains a comprehensive listing of all discovery-stage partnering deals announced since 2020, including financial terms where available. It also features over 2,690 links to detailed online deal records, including publicly available contract documents filed with the SEC.
• By analyzing these agreements, companies gain a competitive edge in structuring deals that align with industry benchmarks while maximizing potential returns.
• Comprehensive Analysis of Discovery-Stage Partnering Trends

The first chapters of the report provide a detailed orientation to discovery-stage deal-making and strategic considerations:

Chapter 1 - Introduction to the report

Chapter 2 - Why companies engage in discovery-stage partnerships

Chapter 3 - Strategic approaches and deal structures, with case studies

Chapter 4 - Payment strategies, including upfronts, milestones, and royalties

Chapter 5 - Discovery-stage deal-making analysis (2020-2025), categorized by year, therapeutic area, technology type, and key dealmakers

Chapter 6 - Detailed analysis of financial terms, including headline values, upfront payments, milestone triggers, and royalty rates

Chapter 7 - A review of the leading discovery-stage deals by headline value

Chapter 8 - The top 25 most active discovery-stage dealmakers

Chapter 9 - A database of discovery-stage partnering agreements, including contract documents where available

Chapter 10 - A comprehensive directory of all discovery-stage deals announced since 2020

• Each deal record is linked to Current Agreements, a proprietary database that provides easy access to full deal structures, financial terms, and contract documents.
• Key Benefits of the Report
• Comprehensive insights into discovery-stage deal trends since 2020
• Access to key financial terms, including headline values, upfronts, milestones, and royalty structures
• Breakdown of deal structures, with real-world case studies
• Analysis of contractual terms, including real-world clause examples
• Benchmarking of deal terms based on actual agreements
• Due diligence insights to assess the suitability of proposed deal terms for potential partners
• Scope of the Report

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report provides:

• Analysis of discovery-stage dealmaking trends in the biopharma industry since 2020
• Insight into financial structures, including upfront, milestone, and royalty payments
• Case studies of real-life discovery-stage agreements
• Access to over 2,690 discovery-stage deals, with contract records where available
• Profiles of the most active discovery-stage dealmakers since 2020
• Detailed analysis of the highest-value discovery-stage deals

Each deal record is indexed by:

• Company (A-Z)
• Headline Value
• Stage of Development at Signing
• Deal Type
• Specific Therapy Focus
• For easy access, every deal record links to an online version, and where available, the full contract document.
• Critical Questions Answered

By analyzing actual contract agreements where available, this report provides definitive answers to critical questions such as:

• What specific rights are granted in each agreement?
• What exclusivity terms apply?
• How is the deal structured financially? (Upfronts, milestones, royalties)
• How are sales and payments audited?
• Who controls development, manufacturing, and commercialization?
• How is intellectual property handled?
• How are confidentiality and publication rights managed?
• Under what conditions can a deal be terminated?
• What dispute resolution mechanisms are in place?
• What happens in the event of a change in ownership?
• Gain the competitive edge-explore the report today.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner at discovery stage?

• 2.1. Introduction
• 2.2. The role of discovery stage partnering
  • 2.2.1. In-licensing at discovery stage
  • 2.2.2. Out-licensing at discovery stage
• 2.3. Difference between discovery, preclinical and clinical stage deals
• 2.4. Reasons for entering into discovery stage partnering deals
  • 2.4.1. Licensors reasons for entering discovery stage deals
  • 2.4.2. Licensees reasons for entering discovery stage deals
• 2.5. The future of discovery stage partnering deals

Chapter 3 - Discovery stage deal strategies and structure

• 3.1. Introduction
• 3.2. At what stage do companies partner?
  • 3.2.1. Partnering early in pharmaceutical/biotech
  • 3.2.1.1. Discovery and preclinical stage partnering case studies
  • 3.2.1.1.a. Case study 1
  • 3.2.1.1.b. Case study 2
  • 3.2.1.1.c. Case study 3
  • 3.2.1.1.d. Case study 4
  • 3.2.2. Partnering later in pharmaceutical/biotech
  • 3.2.2.1. Clinical stage partnering case studies
  • 3.2.2.1.a. Case study 5
  • 3.2.2.1.b. Case study 6
  • 3.2.2.1.c. Case study 7
  • 3.2.2.1.d. Case study 8
• 3.3. Early and later stage partnering - a risk/cost comparison
• 3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
• 3.5. Pure versus multi-component partnering deals
• 3.6. Pure licensing agreement structure
  • 3.6.1. Example pure licensing agreements
  • 3.6.1.a. Case study 9
  • 3.6.1.b. Case study 10
• 3.7. Multicomponent discovery stage partnering agreements
  • 3.7.1.a. Example multicomponent early stage clauses
  • 3.7.1.a. Case study 11
  • 3.7.1.b. Case study 12

Chapter 4 - Discovery stage partnering payment strategies

• 4.1. Introduction
• 4.2. Discovery stage payment strategies
• 4.3. Payment options
  • 4.3.1. Headline values
  • 4.3.2. Upfront payments
  • 4.3.2.1. Conditionality of upfront payments
  • 4.3.3. Loans
  • 4.3.4. Convertible loans
  • 4.3.5. Equity
  • 4.3.6. R&D funding
  • 4.3.7. Licensing fees
  • 4.3.8. Milestone payments
  • 4.3.9. Royalty payments
  • 4.3.9.1. Issues affecting royalty rates
  • 4.3.9.2. Royalties on combination products
  • 4.3.9.2.a. Case study 13
  • 4.3.9.3. Guaranteed minimum/maximum annual payments
  • 4.3.9.4. Royalty stacking
  • 4.3.9.5. Royalties and supply/purchase contracts
  • 4.3.10. Quids
  • 4.3.11. Option payments

Chapter 5 - Trends in discovery stage deal making

• 5.1. Introduction
• 5.2. Discovery stage partnering over the years
  • 5.2.1. Attributes of discovery deals
• 5.3. Discovery stage partnering by deal type
• 5.4. Discovery stage partnering by disease type
• 5.5. Partnering by discovery stage technology type
• 5.6. Discovery stage partnering by most active company, 2020 to 2025

Chapter 6 - Payment terms for discovery stage partnering

• 6.1. Introduction
• 6.2. Guidelines for discovery stage payment terms
  • 6.2.1. Upfront payments
  • 6.2.2. Milestone payments
  • 6.2.3. Royalty payments
• 6.3. Discovery stage payment terms - deal data analysis
  • 6.3.1. Public data
  • 6.3.2. Survey data
• 6.4. Payment terms analysis
  • 6.4.1. Discovery stage headline values
  • 6.4.2. Discovery stage deal upfront payments
  • 6.4.3. Discovery stage deal milestone payments
  • 6.4.4. Discovery stage royalty rates

Chapter 7 - Leading discovery stage deals

• 7.1. Introduction
• 7.2. Top discovery stage deals by value

Chapter 8 - Top 25 most active discovery stage dealmakers

• 8.1. Introduction
• 8.2. Top 25 most active discovery stage dealmakers

Chapter 9 - Discovery stage partnering contracts directory

• 9.1. Introduction
• 9.2. Discovery stage deals with contracts 2020 to 2025

Chapter 10 - Discovery stage deal making by development stage

• 10.1. Introduction
• 10.2. Deals by discovery stage

Appendices

• Appendix 1 - Discovery stage dealmaking by companies A-Z
• Appendix 2 - Discovery stage dealmaking by industry sector
• Appendix 3 - Discovery stage dealmaking by stage of development
• Appendix 4 - Discovery stage dealmaking by therapy area
• Appendix 5 - Discovery stage dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
• Figure 3: Components of the pure licensing deal structure
• Figure 4: Payment options for discovery stage partnering deals
• Figure 5: Issues affecting royalty rates
• Figure 6: Discovery stage partnering frequency 2020 - 2025
• Figure 7: Discovery stage partnering by deal type since 2020
• Figure 8: Discovery stage partnering by disease type since 2020
• Figure 9: Discovery stage partnering by technology type since 2020
• Figure 10: Top 25 most active discovery stage dealmakers, 2020 to 2025
• Figure 11: Review of median upfront payments for discovery stage deals
• Figure 12: Review of median milestone payments for discovery stage deals
• Figure 13: Review of median royalty payments for discovery stage deals
• Figure 14: Discovery stage deals with a headline value
• Figure 15: Discovery stage deals with an upfront value
• Figure 16: Discovery stage deals with a milestone value
• Figure 17: Discovery stage deals with a royalty rate value
• Figure 18: Top discovery stage deals by deal value since 2020
• Figure 19: Most active discovery stage dealmakers 2020 to 2025